voices

Alesha Dixon leapt to the defence of her The Voice UK co-star Cheryl Tweedy after a contestant on Britain’s Got Talent attempted to criticise the Girls Aloud singer

Alesha Dixon instantly supported Cheryl Tweedy following a scathing comment from a Britain’s Got Talent hopeful. Although Alesha is currently appearing on the ITV talent show as a judge, next year she will take on a new role.

The singer will join Stacey Solomon, taking over from Emma Willis, as the pair join forces to host The Voice UK. The singing competition, which also airs on ITV, has undergone a major shake-up, with longstanding coach Sir Jom Jones axed.

Instead, Will.i.am will be returning alongside Kelly Rowland. Girls Aloud singer, Cheryl Tweedy, will join the panel alongside rapper Aitch. And it appears Alesha has already formed a strong bond with Cheryl.

To see more of the stories you love from The Mirror and to find them easily in Google, make us your preferred source. Free and easy to do, just click on the link here to find more from The Mirror at the top of your feed.

During filming for Britain’s Got Talent in Blackpool, it’s reported that a contestant attempted to criticise Cheryl’s vocal abilities. The Sun reports that Alesha hit back instantly.

The Mis-Teeq star slammed her red buzzer halfway through the hopeful’s act and used her feedback to make it clear that she wouldn’t allow his comments. “You don’t come after a mate of mine,” the singer fumed.

Although fans won’t see Cheryl taking on her full-time role as a coach until next year, they were, however, treated to a glimpse earlier this month. The singer joined her pal Will during the Battles Round of the ITV competition.

During the episode, Will revealed that he had been trying to get Cheryl to join him for the past 13 years. Cheryl knows exactly what it takes to make it in the music industry, having found fame after being selected for Girls Aloud on Popstars: The Rivals in 2002.

Speaking to Team Will, the Call My Name songstress said: “I’m so excited for you. You couldn’t be in better hands than you are with my man Will. Will and I have collaborated a lot over the years, so we know what it’s like for two very different artists to come together. I wish you all the very best for what you’ve got today, and I’m excited to see you all!”

Reflecting on her own experience, having found fame on Popstars, Cheryl said during a solo interview: “I have stood in the shoes that the contestants are standing in, and I know what it feels like to perform in this environment. You’ve just got to know that you’re good, or you wouldn’t be here.”

Cheryl’s decision to sign up for the show marks a return to television after a lengthy break from the spotlight. In recent years, Cheryl has turned her attention to family life and has only taken on brief work spells, including her West End debut in 2:22 A Ghost Story.

While she once dominated the music industry and became the first female artist to have five records debut at Number One, her last single, Let You, was released in 2019 and peaked at Number 57 on the Official Charts Company.

Like this story? For more of the latest showbiz news and gossip, follow Mirror Celebs on TikTok, Snapchat, Instagram, Twitter, Facebook, YouTube and Threads.

WASHINGTON — President Trump’s pick to lead the Food and Drug Administration voiced support for the safety of long-established vaccines at a hearing Thursday, even as senators questioned her about the White House’s efforts to upend childhood immunizations.

Dr. Heidi Overton, a physician serving as a White House adviser, has worked on a series of Trump health initiatives, including an executive order last month that called for splitting up and spacing out decades-old childhood vaccinations. Overton stood beside Trump in the Oval Office when he falsely remarked that the combined measles, mumps and rubella, or MMR, vaccine is “quite lethal.”

Senate Health Committee Chairman Sen. Bill Cassidy, a physician from Louisiana, pushed Overton to reject that statement and affirm the safety of FDA-approved vaccines.

“Right now every vaccine that is on the market has been determined to be safe and effective,” including the MMR vaccine, Overton said.

Cassidy repeatedly has tried to extract commitments from Trump health nominees to uphold vaccine standards, including from Health Secretary Robert F. Kennedy Jr., only to see the Republican administration push forward with efforts undermining their use.

“Kennedy gave me guarantees, and he did not keep them,” said Cassidy, a Republican. “If the president asks you to do something that goes against those guarantees you give us today, what will you do?”

Overton said she would “follow the statutory requirements” for FDA commissioners and give Trump her best advice.

If confirmed by the Senate, Overton would inherit a raft of other controversial projects at the agency, including a safety review of the nation’s principal abortion drug and new rules that make it easier to sell flavored electronic cigarettes. Both issues were a focus for Republicans and Democrats on the panel, who will vote on Overton’s nomination.

Overton sidesteps past statements on abortion pill

The FDA approved the abortion pill mifepristone in 2000 and repeatedly has affirmed its safety while broadening access, including allowing it to be sent through the mail. But Kennedy ordered an FDA review of the drug’s safety last year, following calls from antiabortion groups and lawmakers favoring abortion restrictions.

While working at the Trump-aligned America First Policy Institute, Overton called the FDA decision to allow mail delivery of mifepristone “dangerous for women,” referring to the practice as “chemical abortion on demand.”

In response to questions from Washington Sen. Patty Murray, Overton sidestepped her personal views on the drug, stating that it “has met the safety and efficacy determinations of the FDA.” Overton said she didn’t want to “prejudge” the FDA’s safety review of the pill.

“The FDA has said this is safe,” responded Murray, a Democrat. “We need someone in FDA to make sure this is done by science.”

Overton’s abortion views could complicate her efforts to win over two moderate Republicans on the panel: Maine Sen. Susan Collins and Alaska Sen. Lisa Murkowski. Both have bucked their party on the issue, supporting federal access to abortion. Collins is locked in a tight reelection race in which abortion access is a central issue.

But Collins focused her questions Thursday on a different issue: recent FDA decisions allowing new flavored e-cigarettes onto the market. Under previous administrations, including Trump’s first term, the agency had restricted sweet flavors that appeal to kids.

Overton pointed out that approval of the fruit-flavored products had the backing of FDA scientists, who determined the products met the standard of “appropriate for the protection of public health,” by helping adult smokers quit cigarettes.

“They believed that standard was met because so many adult smokers are using flavors preferentially,” Overton said.

To become commissioner, Overton will need a majority of votes from the 21-member health committee, followed by a positive vote from the full Senate.

Under the current administration, leading the agency has involved balancing Trump’s demands for slashing regulations — such as those for vaping products — alongside Kennedy’s interests in scrutinizing vaccines, drugs and food ingredients.

The previous FDA head faced numerous challenges before quitting

Those challenges dogged the tenure of the previous FDA head, Dr. Marty Makary, who resigned in May. Makary’s time at the agency was defined by scientific disputes, leadership changes and a string of media stories detailing low morale and internal dysfunction among staffers. The FDA has lost about 20% of its employees to layoffs, buyouts, retirements or resignations since Trump took office.

Overton studied under Makary at Johns Hopkins University, where she received a doctoral degree in clinical research after earning her medical degree at the University of New Mexico.

Like Makary, Overton has no experience running a large bureaucracy, a critical skill for steering the FDA’s 16,000 staffers spread across numerous U.S. and international locations.

In financial disclosure forms, Overton reported no investments in healthcare or food companies. That’s a stark contrast to Makary and other recent FDA nominees who have had to divest investments or cut other financial ties with companies regulated by the FDA.

Overton reported $50,000 to $100,000 in student loans.

Perrone writes for the Associated Press.